Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReyaGel
- Development stage
- Unknown
- Lead developer
- FetTech
- Administration
- Topical
01
Overview
ReyaGel is an FDA-cleared liquid extracellular matrix (ECM) product developed by FetTech, LLC, utilizing their proprietary Multi-Tissue Platform (MTP) technology. It is composed of porcine spleen and lung-derived ECM, containing structural proteins like collagen and elastin along with various growth factors, formulated in a saline gel. ReyaGel is designed to support the body's natural regenerative healing processes by providing a biological scaffold that reduces inflammation, minimizes scarring, and enhances tissue recovery. It received 510(k) clearance in 2024 for the management of partial and full-thickness wounds and is also utilized in aesthetic applications, including post-procedural skin recovery (e.g., after CO2 laser or microneedling) and hair restoration.
- Brand names
- ReyaGel
Beyond the preview
Go deeper on ReyaGel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReyaGel.